| Title |
Belimumab Therapy in Systemic Lupus Erythematosus
|
|---|---|
| Published in |
BioDrugs, April 2013
|
| DOI | 10.1007/s40259-013-0031-8 |
| Pubmed ID | |
| Authors |
Moncef Zouali, Eugene A. Uy |
| Abstract |
Systemic lupus erythematosus (SLE) is a complex heterogeneous disease, posing challenges to clinical trials. As in other autoimmune diseases, B-lymphocytes play a central role in lupus pathogenesis. The finding that selection and survival of B cells are controlled by a variety of signals, including those provided by the longevity factor BAFF (B-cell activating factor), also called BLyS (B-lymphocyte stimulator), led to preclinical trials that revealed that BAFF represents a promising therapeutic target for human lupus. Belimumab is a fully human monoclonal antibody directed against BAFF. Lessons learned from early clinical trials led to improved methods and success of phase III trials, with recruitment of patients with both clinically and serologically active disease, development and use of a novel SLE Responder Index, and progressive and special restrictions on immunosuppressive and corticosteroid use. These studies offer an attractive blueprint to conduct future clinical trials in SLE. The overall steroid-sparing ability and benefits of belimumab on musculoskeletal and mucocutaneous organ systems suggest that it has an impact on the clinical management of SLE patients. Future directions include studies to determine the role of belimumab in early SLE, as well as in renal or CNS involvement. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 19% |
| Lecturer > Senior Lecturer | 1 | 6% |
| Other | 1 | 6% |
| Unspecified | 1 | 6% |
| Student > Ph. D. Student | 1 | 6% |
| Other | 3 | 19% |
| Unknown | 6 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 25% |
| Psychology | 2 | 13% |
| Unspecified | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Economics, Econometrics and Finance | 1 | 6% |
| Other | 2 | 13% |
| Unknown | 5 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2013.
All research outputs
#18,341,369
of 22,713,403 outputs
Outputs from BioDrugs
#564
of 645 outputs
Outputs of similar age
#151,058
of 199,340 outputs
Outputs of similar age from BioDrugs
#14
of 18 outputs
Altmetric has tracked 22,713,403 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 645 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,340 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.